Literature DB >> 35585

Long-term haloperidol-treatment of mice: a change in beta-adrenergic receptor responsiveness.

R Dunstan, D M Jackson.   

Abstract

Mice administered haloperidol 3 mg/kg/day in their drinking water for 21 days were tested for their locomotor responsiveness to saline or acid vehicle, dl-, l- or d-propranolol, metoprolol, butoxamine or practolol. Haloperidol-treated animals administered saline or acid-vehicle were, in five of six experiments, more active than animals withdrawn from vehicle-treatment. Haloperidol- and vehicle-treated animals responded differently to the non-selective beta-adrenoreceptor antagonists (dl-propranolol and l-propranolol) and selective beta1-adrenoreceptor antagonists (practolol and metoprolol), but not to a selective beta2-adrenoreceptor antagonist (butoxamine). With dl-propranolol (4 mg/kg) the locomotor activity of haloperidol-treated animals was significantly (0.01 less than P less than 0.02) greater than that of the vehicle-treated animals. Similar effects in the same direction were seen with l-propranolol (1 mg/kg, 0.005 less than P less than 0.01), practolol (10 and 100 mg/kg, 0.025 less than P less than 0.05 and 0.01 less than P less than 0.025 respectively) and metoprolol 8 mg/kg, 0.005 less than P less than 0.01). The d-isomer of propranolol which is about 50 times less active as a beta-adrenoreceptor antagonist than the l-isomer, although having equal membrane stabilizing effects, did not differentially affect haloperidol- or vehicle-treated groups. The results suggest that there has been a change in beta 1-adrenoreceptor responsiveness in animals withdrawn from long-term haloperidol treatment.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 35585     DOI: 10.1007/bf01253062

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  24 in total

1.  Direct identification and characterisation of beta-adrenergic receptors in rat brain.

Authors:  R W Alexander; J N Davis; R J Lefkowitz
Journal:  Nature       Date:  1975-12-04       Impact factor: 49.962

2.  Direct localisation of beta-adrenoceptor sites in rat cerebellum by a new fluorescent analogue of propranolol.

Authors:  E Melamed; M Lahav; D Atlas
Journal:  Nature       Date:  1976-06-03       Impact factor: 49.962

3.  Modification by two beta-adrenergic blocking drugs of the effects of methamphetamine on behaviour and brain metabolism of mice.

Authors:  C J Estler; H P Ammon
Journal:  J Neurochem       Date:  1971-05       Impact factor: 5.372

4.  Absence of central nervous system effects of practalol [ICI 50,172; 4-(2-hydroxy-3-isopropylaminopropoxy)-acetanilide], a new adrenergic beta-receptor blocking drug.

Authors:  C J Estler; H P Ammon
Journal:  J Pharm Pharmacol       Date:  1969-08       Impact factor: 3.765

5.  An investigation of a new instrument to measure motor activity of small animals.

Authors:  T H Svensson; G Thieme
Journal:  Psychopharmacologia       Date:  1969

6.  Effects of propranolol on some activities of amphetamine.

Authors:  P Mantegazza; K M Naimzada; M Riva
Journal:  Eur J Pharmacol       Date:  1968-08       Impact factor: 4.432

7.  Selective beta adrenergic receptor antagonism in the anesthetized dog.

Authors:  M A Wasserman; B Levy
Journal:  J Pharmacol Exp Ther       Date:  1974-02       Impact factor: 4.030

8.  The effect of apomorphine and clonidine on locomotor activity in mice after long term treatment with haloperidol.

Authors:  R Dunstan; D M Jackson
Journal:  Clin Exp Pharmacol Physiol       Date:  1977 Mar-Apr       Impact factor: 2.557

Review 9.  Central hypotensive effect of propranolol.

Authors:  C T Dollery; P J Lewis
Journal:  Postgrad Med J       Date:  1976       Impact factor: 2.401

10.  The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias.

Authors:  A M Barrett; V A Cullum
Journal:  Br J Pharmacol       Date:  1968-09       Impact factor: 8.739

View more
  5 in total

1.  Changes of response to dopaminergic drugs in rats submitted to REM-sleep deprivation.

Authors:  S Tufik
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

2.  The effect of chronic haloperidol treatment on some cardiovascular parameters in cats.

Authors:  G A Bentley; I W Copeland
Journal:  Br J Pharmacol       Date:  1985-11       Impact factor: 8.739

3.  Chronic haloperidol and adrenergic receptor sensitivity in the rat.

Authors:  A Perrington; R Einstein; D M Jackson; M J Christie
Journal:  J Neural Transm       Date:  1983       Impact factor: 3.575

4.  Chronic treatment with chlorpromazine, thioridazine or haloperidol increases striatal enkephalins and their release from rat brain.

Authors:  Z S Herman; M Huzarska; K Kmieciak-Kolada; J Kowalski
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

5.  Evaluating early preventive antipsychotic and antidepressant drug treatment in an infection-based neurodevelopmental mouse model of schizophrenia.

Authors:  Urs Meyer; Erica Spoerri; Benjamin K Yee; Markus J Schwarz; Joram Feldon
Journal:  Schizophr Bull       Date:  2008-10-08       Impact factor: 9.306

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.